Sofcare 5

Sofcare 5

solifenacin

Manufacturer:

Unison

Distributor:

Medispec
Concise Prescribing Info
Contents
Solifenacin succinate
Indications/Uses
Symptomatic treatment of urge incontinence &/or increased urinary frequency & urgency in patients w/ overactive bladder syndrome.
Dosage/Direction for Use
Adult including elderly 5 mg once daily, may be increased to 10 mg once daily. Severe renal impairment (CrCl ≤30 mL/min) & moderate hepatic impairment (Child-Pugh 7-9) Max: 5 mg once daily.
Administration
May be taken with or without food: Swallow whole w/ liqd.
Contraindications
Hypersensitivity. Urinary retention, severe GI condition including toxic megacolon, myasthenia gravis, narrow-angle glaucoma. Concomitant use w/ potent CYP3A4 inhibitor eg, ketoconazole. Patients undergoing haemodialysis. Severe renal & moderate to severe hepatic impairment.
Special Precautions
Discontinue use if anaphylactic reactions develop & angioedema occurs. Clinically significant bladder outflow obstruction at risk of urinary retention; GI obstructive disorders; risk of decreased GI motility; hiatus hernia/GERD; autonomic neuropathy. Patients w/ neurogenic cause for detrusor overactivity; known risk factors for QT prolongation ie, history of QT prolongation, long QT syndrome, hypokalaemia, bradycardia; relevant pre-existing cardiac diseases ie, myocardial ischaemia, arrhythmia, CHF. May cause serious allergic-type reactions due to Na metabisulfite. Concomitant use w/ potent CYP3A4 inhibitor eg, ketoconazole; medicinal products causing or exacerbating oesophagitis eg, bisphosphonates. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May affect ability to drive & use machines. Severe renal (CrCl ≤30 mL/min) & moderate hepatic (Child-Pugh score 7-9) impairment. Pregnancy. Avoid use during lactation. Not to be used in childn.
Adverse Reactions
Dry mouth. Blurred vision; constipation, nausea, dyspepsia, abdominal pain.
Drug Interactions
Reduced therapeutic effect w/ cholinergic-receptor agonists. Reduced effect of drugs stimulating GI tract motility eg, metoclopramide, cisapride. Increased AUC w/ ketoconazole, ritonavir, nelfinavir, itraconazole. CYP3A4 substrates w/ higher affinity eg, verapamil, diltiazem; CYP3A4 inducers eg, rifampicin, phenytoin, carbamazepine.
MIMS Class
Drugs for Bladder & Prostate Disorders
ATC Classification
G04BD08 - solifenacin ; Belongs to the class of urinary antispasmodics.
Presentation/Packing
Form
Sofcare 5 FC tab 5 mg
Packing/Price
3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in